William Blair analyst Brandon Vazquez has maintained their bullish stance on EW stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Vazquez has given his Buy rating due to a combination of factors surrounding the recent data presented at the TCT 2025 conference. The seven-year data from the Partner 3 study was a focal point, showing that the all-cause mortality gap between Transcatheter Aortic Valve Replacement (TAVR) and surgery remained stable, despite some non-TAVR related events affecting the TAVR group. Importantly, the hemodynamics and durability of TAVR were comparable to surgery, supporting its continued adoption among low-risk patients.
Additionally, new 10-year data on intermediate-risk patients showed that newer valve models like Sapien 3 have noninferior outcomes compared to surgery, even on significant endpoints such as all-cause mortality. Although long-term follow-up presents challenges due to the advanced age of patients, the data suggests that TAVR remains a viable and competitive option. These findings contribute to the positive outlook for Edwards Lifesciences, reinforcing the Buy rating.
According to TipRanks, Vazquez is an analyst with an average return of -2.9% and a 30.30% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Ceribell, Inc., Align Tech, and Dexcom.
In another report released yesterday, Barclays also maintained a Buy rating on the stock with a $95.00 price target.